NRG|PALLAS and TAG1 Inc. Partner To Expand Pb-212 Production

NRGIPALLAS (ENS Corporate Member) and TAG1 Inc. have signed a multi-year partnership to secure a critical supply of radium-224 for the production of lead-212 (Pb-212) isotope.

This agreement aims to strengthen the supply chain for innovative radiopharmaceutical cancer treatments, including Targeted Alpha Therapies (TATs), which hold great promise for treating tumours that have been traditionally difficult to target.

Lead-212 is increasingly recognized for its role in TATs, offering precision treatments by delivering potent alpha particles directly to cancerous cells while sparing healthy tissue.

This innovative collaboration will bolster the availability of critical isotopes, supporting the development and delivery of life-saving therapies to cancer patients.

This partnership secures a reliable supply chain for these critical isotopes, supporting advancements in clinical applications and commercial efforts, and helping to shape the future of cancer care.

Vinod Ramnandanlal, commercial director of NRG Pallas, said.

Read the full NRG|PALLAS Press Release.

Nuclear medicine and medical isotopes benefit thousands of patients every day in current clinical practice and have great potential for future clinical challenges.

Last year, ENS, together with Euratom Supply Agency (ENS Member), organised the event Beating Cancer – turning the tide with medical isotopes, which gave us the opportunity to learn more about those amazing developments and to discuss the challenges ahead.

You can find its recording and all materials in our Special Newsletter.